[O3] Oral Session 3　血液
【E】

[O3-3] Subcutaneous Epcoritamab + R-CHOP in Previously Untreated High-Risk DLBCL: Preliminary Results From a Phase 1/2 Trial

^○David Belada¹, Jacob H. Christensen², Kristina Drott³, Sylvia Snauwaert⁴, Joshua Brody⁵, Mayur Narkhede⁶, Fritz Offner⁷, Brian Elliott⁸, Tracy Liu⁸, Mariana Cota Stirner⁹, Aqeel Abbas⁸, Lorenzo Falchi¹⁰, Michael Roost Clausen¹¹ (1.4th Department of Internal Medicine-Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic, 2.Odense University Hospital, Odense, Denmark, 3.Skane University Hospital, Scania, Sweden, 4.Department of Hematology, AZ Sint-Jan Hospital, Bruges, Belgium, 5.Icahn School of Medicine at Mount Sinai, New York, NY, USA, 6.O’Neal Comprehensive Cancer Center at UAB, Birmingham, AL, USA, 7.Universitair Ziekenhuis Gent, Ghent, Belgium, 8.Genmab, Princeton, NJ, USA, 9.AbbVie, North Chicago, IL, USA, 10.Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA, 11.Vejle Hospital, Vejle, Denmark)